Fri, Oct 31, 2014, 2:11 PM EDT - U.S. Markets close in 1 hr 49 mins

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

beavertail_splash 446 posts  |  Last Activity: 23 minutes ago Member since: Apr 13, 2007
  • beavertail_splash beavertail_splash Oct 4, 2014 10:43 PM Flag

    ...no conflict of interest here?
    Ouch, I just hit my head on a sharp tree stump.

  • beavertail_splash beavertail_splash Oct 4, 2014 10:39 PM Flag

    E2W what about the MAYO's earlier publication on Jakafi's more serious side effects including withdrawl symptoms?
    Ayalew Tefferi, explained earlier that ruxolitinib is suitable for only some patients with myelofibrosis, possibly only 25%. Even then it might not be the best option, he said. In the 25% group of patients present with low-grade disease that don't require immediate action., treatment could kill the patients faster than the disease would.
    Ayalew Tefferi interview with Medscape Medical News;
    "Now, however, comments from an expert not involved in either of the 2 pivotal studies, but who was involved in an earlier phase 1/2 study of the drug, temper some of this enthusiasm. In his editorial accompanying the 2 studies, Ayalew Tefferi, MD, from the division of hematology at the Mayo Clinic, explained that ruxolitinib is suitable for only some patients with myelofibrosis, possibly only 25%. Even then it might not be the best option, he said.
    Dr. Tefferi pointed out that ruxolitinib does not affect the underlying disease, and offers only transient palliation of some symptoms.(spleen size) In addition, he maintains that it does not improve survival, and points out that it has adverse effects, including myelosuppression, withdrawls and is expensive.
    However, ruxolitinib is not the only option, he emphasized. These patients could also be offered a transplant (with something like a 50% chance of kill or cure), or other available therapies such as hydroxyurea, or they could be offered investigational agents, including new and improved JAK inhibitors, which might be better than ruxolitinib, but which are free because they are research drugs that are in clinical trials. Why would a patient who is eligible for a clinical trial and for whom there is no impediment to participation (e.g., such as distance) want to take ruxolitinib, he asked." of course his new & improved inhibitor reference was to IMET.

  • Reply to

    Jakafi Spin

    by frhornwoman Oct 1, 2014 9:55 PM
    beavertail_splash beavertail_splash Oct 2, 2014 2:07 AM Flag

    The MAYO Clinic agrees with your "sense" on Jakafi (Soylent Green)
    MAYO ABSTRACT;
    "Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials. In 2 recent communications that focused on short-term and long-term ruxolitinib treatment outcome, respectively, the drug was shown to be effective in controlling constitutional symptoms and splenomegaly but was also associated with important adverse effects, including moderate to severe thrombocytopenia and anemia. The most recent of the 2 communications focused on 51 Mayo Clinic patients who participated in the original phase 1/2 ruxolitinib clinical trial and highlighted a high treatment discontinuation rate (92% after a median time of 9.2 months), primarily for loss of treatment benefit but also because of drug-associated adverse effects. The report also discussed the occurrence of sometimes severe withdrawal symptoms during ruxolitinib treatment discontinuation. This "ruxolitinib withdrawal syndrome" was characterized by acute relapse of disease symptoms, accelerated splenomegaly, worsening of cytopenias, and occasional hemodynamic decompensation, including a septic shocklike syndrome. In the current sponsor-independent analysis, we describe the details of these events in 5 severely affected cases (11%) among 47 Mayo Clinic patients with MF in whom ruxolitinib therapy had been discontinued. Our experience calls for full disclosure of the ruxolitinib withdrawal syndrome to patients with MF before initiating ruxolitinib therapy, and treatment discontinuation must be done under close physician supervision and preferably in a tapering schedule."

  • Reply to

    IMET Phase II?

    by blackmarango Oct 1, 2014 8:50 AM
    beavertail_splash beavertail_splash Oct 2, 2014 1:50 AM Flag

    labeling the MAYO MF 1ST trial also adds to this confusion.

  • beavertail_splash by beavertail_splash Oct 1, 2014 8:25 PM Flag

    BREAKDOWN WATCH for possible breakdown below 1.69, no support in area just below.
    Type: True breakdown from Triple+ support.
    Target: 1.17, 38.7% Cover: 2.11, Loss: 10.5%, Profit/Loss ratio: 3.7 : 1 - Excellent

    GERN's now in the same trading range as when the FDA announced their clinical hold. :=3(

  • beavertail_splash beavertail_splash Oct 1, 2014 1:46 AM Flag

    ...stay tuned, GERN pond critters everywhere.

  • beavertail_splash beavertail_splash Oct 1, 2014 1:15 AM Flag

    if you look at the technical the trend support line(FINVIZ blue line) that wasn't apparent till today appeared miraculously. It crossed over the trend resistant line back on Sept.15th. The cross over point was @ $2.50. Prior to this the SP was trading above the trend support line, Which made sense with the hand over of the MAYO MF trial back to GERN. After the 15th, with all the naked shorting that jumped in the game SP dropped down to $2.00 today. This is below both support and resistant trend lines reflecting a perversion of the normal trading patterns in the stock. We are grossly undervalued at this juncture and 'incisors' can cut down paper shorts anytime, especially given any rock solid news.

  • Reply to

    Any suggestions...

    by fmotiie Sep 30, 2014 4:52 PM
    beavertail_splash beavertail_splash Sep 30, 2014 9:47 PM Flag

    She went missing over the Pacific. Artifacts recovered by TIGHAR during 10 expeditions have suggested that Earhart and her navigator, Fred Noonan, did not crash in the Pacific Ocean, running out of fuel somewhere near Howland Island and became castaways on an atoll, which is some 350 miles southeast of Howland Island their target destination.

  • Reply to

    OT - Beav

    by betting_freddy Sep 30, 2014 5:35 PM
    beavertail_splash beavertail_splash Sep 30, 2014 9:15 PM Flag

    Freddy the only ones wearing the pants around here are the longs. It's open season on shorts. ;=3E)

  • beavertail_splash beavertail_splash Sep 30, 2014 5:36 PM Flag

    There you are and yes looks like my dam is holding despite that hedgehogs water pumps draining all the water today.

  • beavertail_splash beavertail_splash Sep 30, 2014 5:29 PM Flag

    The Institutional Review Board better not be stacked with INCY's lobbyists like the MPN forum is. Doesn't this appear to be a fast track pathway to BAT designation Irish?

  • beavertail_splash beavertail_splash Sep 30, 2014 5:19 PM Flag

    There are two IND trials now listed on company's web-site
    both are in phase ll. Neither are taking new patients.
    1. Essential thrombocythemia or Polycythemia vera Imetelstat Phase 2 Closed to patient enrollment and on clinical hold United States, Germany & Switzerland
    see ClinicalTrials.gov
    2. Myelofibrosis Imetelstat Phase 2 Closed to patient enrollment United States (Mayo Clinic) BUT IS NOT ON HOLD! This looks like fast traking for BAT is in place.
    Expect great news soon, especially after the 'non-news' bear raid today. All those naked shorts running fur cover. ;=3)
    Irish MF is no longer the 'never ending phase l trial' but has become the shortest phase ll. Onto phase lll passing GO and collecting our $200! We've been sitting in monopoly shareholder jail far too long. Park Ave and Broadway...here comes the GERN train. (Park Lane & Windsor Castle if U play the English version)
    see ClinicalTrials.gov

  • Reply to

    ASH (Imetelstat, 2014)=Truth

    by sidesaddlex Sep 24, 2014 10:31 AM
    beavertail_splash beavertail_splash Sep 30, 2014 2:11 AM Flag

    Carmen Segarra is a former New York Federal Reserve bank examiner who butted heads with her bosses over her policing of Goldman Sachs. She lost her job like Brooksley Born because she was doing her job to enforce the FED's required reporting by these banks. When a conflict of interest was exposed by her in the Fed reserve over their refusal to police such matters with Goldman Sachs she was dismissed from her job. Segarra’s case raises a host of questions about “regulatory capture”, the term for regulators who become too cozy with the industry they are meant to police. Goldman Sachs is in damage control mode AGAIN!

  • beavertail_splash beavertail_splash Sep 29, 2014 8:11 AM Flag

    well it would certainly turnaround Blackmango's view on Chippy. A $20 buyout would be nice. Otherwise I would tend to agree with Blackmamba that Chippy's compensation is tied into salary too much and not enough is reflected in his share holdings(lack of). If he was paid strictly in shares one wonders if we would be so far down in the doghouse.

  • beavertail_splash beavertail_splash Sep 29, 2014 1:06 AM Flag

    all we need to do is pressure congress to give them authority to regulate. The SEC needs back it's dentures for it to be able to bite.

  • beavertail_splash beavertail_splash Sep 29, 2014 12:59 AM Flag

    Meliorist this IS within domain of the SEC
    read TERRY SCHLEMEIER's article on Brooksley Born's career from president of a law review in the United States to being appointed head of the CFTC. The Commodity Futures Trading Commission, a somewhat "obscure agency charged with “protecting market users, and the public, from fraud, manipulation and abusive practices, related to the vast array of financial instruments.”
    Born intuitive and smart immediately "noted there were approximately $70 trillion of derivatives being traded on the market without any regulation or supervision in place and said publicly she would begin writing regulations to control the sale and accountancy of such activity.
    The “big boys”; Fed Chairman Alan Greenspan, Treasury Secretary Robert Rubin, Deputy Treasury Secretary Larry Summers and Arthur Levitt, chairman of the SEC collectively decided to de-tooth her authority & mussel her stating she "didn’t know what she was doing.”
    Later Larry Summers called Born at her office and said: “I have 13 bankers in my office, and they say if you go forward with this (regulations), you will cause the worst financial disaster since World War II.”
    Born responded by writing a position paper and proposed regulations of the derivative market. The courage it took for her to defy Greenspan, who was called the “Oracle” in the mid-’90s, and the other gang members required more than brass balls.
    "Alan Greenspan and his gang were successful in prompting Congress to write a resolution prohibiting the CFTC from issuing any rules governing the derivative market. If you can’t do your job, you quit, which is exactly what Born did in 1999." This allowed the set up for the derivatives crisis to develop unchecked by any govt. regulators allowed the derivative crisis to develop "causing the worst financial disaster since World War II"
    Had Born been allowed to enforce regulation of derivatives we would not be in the $18 trillion debt crisis we have today.

  • beavertail_splash beavertail_splash Sep 29, 2014 12:18 AM Flag

    I'm a beaver Mr Magoo...I build dams to store precious water and create a home & clean environment to allow for many pond critters to flourish. By stealing the sticks of my labour the dam breaks down causing a deluge drowning everything in it's wake....sort of like in the story of Noah. If we as a society allow such travesty to continue unabated we are doomed to all become caged monkeys.

  • beavertail_splash beavertail_splash Sep 28, 2014 5:05 PM Flag

    Comsense wonder how long they'll allow this up for? It looks ditto to what we've experienced here in GERN wrt the high (18%) short numbers piling in after last years ASH news conference and doubling after the FDA hold announcement. Wonder if these hedgefunds had anything to do with that?

  • beavertail_splash beavertail_splash Sep 28, 2014 4:57 PM Flag

    my original response to your post Pedmac was remove. I was comparing the hedge short fund activity citied in the article about northwest bio to that of GERN's;" a handful of hedge funds anonymously drive down the price by selling borrowed shares into the market at the same time, creating a self-fulfilling momentum that scares off other investors. Even when they can’t get a hold of enough borrowed shares, they might sell the shares anyway and simply fail to deliver them three days later when they are due. That’s known as a “naked” short, and it’s illegal"
    The timing of hit pieces in the media;" the shorts are active in anonymously feeding false and misleading information about their target companies to friendly analysts and bloggers while using social media to attack the intelligence and motives of those who view the company favorably. They enlist plaintiffs law firms to issue press releases soliciting shareholders to sue the target companies for securities fraud. And they pepper regulators with threatening letters and fillings demanding that they investigate their targets or deny them product approvals."
    The SEC is asleep at their job to allow such criminal behaviour to run rampant in the American Investment market. These hedge funds eliminate potential cancer cures and potentially safer treatment , allowing countless people that could benefit from this tech development to die so that they can profit. Worse than terrorists. Is it any wonder these hedge fund collectively controls 4.5 trillions in assets. Black Rock's asset worth for 2014 was 4.5 trillion worth.

  • beavertail_splash beavertail_splash Sep 28, 2014 12:15 PM Flag

    Farstain and such hedge fund activity needs to be investigated by the sector if the market is to regain any sense of credibility. Now it's one big casino play with the roulette wheel being rigged by the house players.

TSRX
13.63-0.05(-0.37%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.